HP PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
HP PHARMA
Largest movements
- Receivables within one year -€287,762
down €287,762 (-87.9%), from €327,560 to €39,798
of which Other amounts receivable: -€274,981
- Other debts -€140,032
down €140,032 (-48.0%), from €291,594 to €151,562
- Debts after one year -€92,671
down €92,671 (-47.7%), from €194,404 to €101,734
- Reserves -€48,673
down €48,673 (-14.4%), from €339,076 to €290,404
- Gross operating margin -€25,648
down €25,648 (-24.6%), from €104,071 to €78,423
- Staff costs -€22,828
down €22,828 (-54.0%), from €42,312 to €19,485
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,065,142 | €778,484 | -€286,658 | -26.9% |
| Fixed assets | 21/28 | €731,312 | €731,147 | -€165 | 0.0% |
| Tangible fixed assets | 22/27 | €1,363 | €1,198 | -€165 | -12.1% |
| Other tangible fixed assets | 26 | €1,363 | €1,198 | -€165 | -12.1% |
| Financial fixed assets | 28 | €729,949 | €729,949 | = | 0.0% |
| Current assets | 29/58 | €333,830 | €47,337 | -€286,493 | -85.8% |
| Amounts receivable within one year | 40/41 | €327,560 | €39,798 | -€287,762 | -87.9% |
| Trade receivables | 40 | €38,190 | €25,409 | -€12,780 | -33.5% |
| Other amounts receivable | 41 | €289,370 | €14,389 | -€274,981 | -95.0% |
| Cash at bank and in hand | 54/58 | €16 | €1,820 | +€1,803 | +10948.2% |
| Deferred charges and accrued income | 490/1 | €6,254 | €5,719 | -€535 | -8.5% |
| Total equity and liabilities | 10/49 | €1,065,142 | €778,484 | -€286,658 | -26.9% |
| Equity | 10/15 | €440,530 | €391,858 | -€48,673 | -11.0% |
| Contributions | 10/11 | €20,000 | €20,000 | = | 0.0% |
| Reserves | 13 | €339,076 | €290,404 | -€48,673 | -14.4% |
| Distributable reserves | 133 | €339,076 | €290,404 | -€48,673 | -14.4% |
| Profit (loss) carried forward | 14 | €81,454 | €81,454 | = | 0.0% |
| Amounts payable | 17/49 | €624,612 | €386,626 | -€237,986 | -38.1% |
| Amounts payable after more than one year | 17 | €194,404 | €101,734 | -€92,671 | -47.7% |
| Financial debts | 170/4 | €194,404 | €101,734 | -€92,671 | -47.7% |
| Amounts payable within one year | 42/48 | €409,636 | €264,565 | -€145,071 | -35.4% |
| Current portion of amounts payable after more than one year | 42 | €95,709 | €92,127 | -€3,582 | -3.7% |
| Trade debts | 44 | €2,546 | €8,982 | +€6,436 | +252.8% |
| Suppliers | 440/4 | €2,546 | €8,982 | +€6,436 | +252.8% |
| Taxes, remuneration and social security | 45 | €19,787 | €11,894 | -€7,893 | -39.9% |
| Taxes | 450/3 | €11,946 | €11,894 | -€52 | -0.4% |
| Remuneration and social security | 454/9 | €7,841 | - | -€7,841 | |
| Other amounts payable | 47/48 | €291,594 | €151,562 | -€140,032 | -48.0% |
| Accrued charges and deferred income | 492/3 | €20,571 | €20,328 | -€244 | -1.2% |
| Remuneration, social security and pensions | 62 | €42,312 | €19,485 | -€22,828 | -54.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €121 | €165 | +€44 | +36.0% |
| Other operating charges | 640/8 | €240 | €877 | +€637 | +265.3% |
| Gross operating margin | 9900 | €104,071 | €78,423 | -€25,648 | -24.6% |
| Operating profit (loss) | 9901 | €61,397 | €57,897 | -€3,501 | -5.7% |
| Financial charges | 65/66B | €27,504 | €28,213 | +€709 | +2.6% |
| Recurring financial charges | 65 | €27,504 | €28,213 | +€709 | +2.6% |
| Profit (loss) for the period before taxes | 9903 | €33,893 | €29,684 | -€4,210 | -12.4% |
| Income taxes | 67/77 | €7,607 | €8,443 | +€836 | +11.0% |
| Profit (loss) for the period | 9904 | €26,286 | €21,240 | -€5,046 | -19.2% |
| Profit (loss) for the period to be appropriated | 9905 | €26,286 | €21,240 | -€5,046 | -19.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.